Cellular immunotherapies developer Carma Therapeutics has completed a venture financing round co-led by AbbVie Biotech Ventures and HealthCap in order to raise funds required to advance the development of its adoptive cellular immunotherapy named CARMA-0508.

The round also saw the participation of Grazia Equity and IP Group.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Taiwanese biotechnology company Vectorite Biomedica plans for a rights offering of shares of its common stock to raise TWD41.63m ($1.37m) in gross proceeds.

The company will issue 2.5 million new shares priced at TWD18.5 ($0.6) each as part of the offering.

The company’s employees will be issued 10% of the shares, the equivalent of 250,000 shares, while the remaining will be issued to the existing shareholders.

See Also:

"Taiwanese biotechnology company Vectorite Biomedica plans for a rights offering of shares of its common stock to raise TWD41.63m ($1.37m) in gross proceeds."

The proceeds from the offering will be used for working capital purposes.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

US-based biopharmaceutical company Loxo Oncology has announced an underwritten public offering of shares of its common stock to raise funds needed for early commercialisation of larotrectinib, research and development activities, and general corporate purposes.

Underwriters for the offering will be granted an option to purchase additional shares within 30 days.

Aequus Pharmaceuticals and Santen Pharmaceutical’s subsidiary Santen has signed an agreement for the commercialisation of an undisclosed ophthalmology therapeutic product in Canada that currently awaits Health Canada’s marketing approval.

Aequus Pharmaceuticals is a specialist Canadian pharmaceutical company, while Santen is an ophthalmology company based in the US.